The Future of ADOA: Clinical Trials and New Science

We are currently in a “golden age” of genetic research, and Autosomal Dominant Optic Atrophy (ADOA) is at the forefront of several groundbreaking scientific approaches. While we are still in the testing phases, the pipeline for new treatments is moving from the lab into clinical trials with real patients.

Boosting Protein Production: ASOs

The most common cause of ADOA is haploinsufficiency, where the body simply doesn’t make enough OPA1 protein ^[1]. To fix this, researchers are developing Antisense Oligonucleotides (ASOs), such as STK-002 or PYC-001 ^[2][3].

These are small, laboratory-made molecules designed to “speak” to your genetic machinery. Instead of replacing a gene, they “trick” the healthy copy of your OPA1 gene into working harder, effectively doubling its protein output to reach normal levels ^[2][1]. Some of these therapies are already in Phase 1 clinical trials, testing their safety through injections into the eye [NCT06970106].

Gene Therapy and “Variant-Agnostic” Approaches

While traditional gene therapy often tries to replace a specific “broken” gene, new research is exploring variant-agnostic therapies ^[4]. This means the treatment is designed to work for everyone with ADOA, regardless of their specific type of OPA1 mutation. Researchers are also investigating CRISPR gene editing, which acts like a “molecular eraser and pencil” to fix the mutation directly within the DNA of the eye’s cells ^[3].

Small Molecules and Mitochondrial Protection

In addition to genetic “fixes,” scientists are testing drugs that protect the mitochondria from the energy crisis that causes cell death:

• NAD+ Boosters (Nicotinamide): Nicotinamide (a form of Vitamin B3) is essential for energy production. Early studies suggest that high-dose nicotinamide may help protect the optic nerve from damage by boosting its energy supply ^[5][NCT0607391].
• DRP1 Inhibitors: In ADOA, mitochondria become too fragmented (broken apart). Drugs that inhibit a protein called DRP1 can help stop this fragmentation, keeping the mitochondria in their healthy, long-network shapes ^[6].
• SARM1 Inhibitors: Researchers have identified a “neurodegeneration switch” called SARM1 that turns on when mitochondria are failing. By inhibiting this switch, they hope to stop the retinal ganglion cells from dying, even if the mitochondria are still struggling ^[7].

How to Get Involved

Because ADOA is rare, researchers need patients to participate in Natural History Studies [NCT01793168]. These studies don’t involve a new drug; instead, they track how the disease progresses over time. Joining a registry like CoRDS is one of the best ways to ensure you are notified as soon as a treatment that matches your genetic profile enters a clinical trial [NCT01793168].